Objective: This single-arm Phase II trial was designed to assess the safety and efficacy of pegylated liposomal doxorubicin and carboplatin combination chemotherapy in patients with platinumsensitive recurrent ovarian cancer. Methods: Patients with a histological diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma, who were relapse-free at least 6 months after completion of first-line platinumbased chemotherapy, and who had measurable disease and gave consent to participate in this study received infusions of pegylated liposomal doxorubicin (30 mg/m 2 ) at 1 mg/min, followed by carboplatin (AUC 5 mg min/ml) over 30 min every 28 days.
Introduction
The standard chemotherapy for recurrent, platinum-sensitive ovarian cancer that responds to first-line therapy but relapses >6 months after completion of initial, platinum-based chemotherapy is re-treatment with first-line therapy. The Caelyx in Platinum-Sensitive Ovarian Patients (CALYPSO) study (1) , which recently enrolled patients in Europe, Australia and New Zealand, demonstrated higher survival rates and a larger therapeutic index after treatment with pegylated liposomal doxorubicin (PLD) and carboplatin (CBDCA), when compared with treatment with paclitaxel (PTX) and CBDCA in patients with platinum-sensitive recurrent ovarian cancer. The study made a significant impact on the treatment of ovarian cancer, although the safety and efficacy of PLD + CBDCA for Asian patients still remains unclear.
This single-arm Phase II trial was specifically designed to assess the safety and efficacy of PLD + CBDCA combination chemotherapy in patients with platinum-sensitive recurrent ovarian cancer in Japan. This study is registered with the UMIN Clinical Trials Registry as trial UMIN000002691, on 29 October 2009.
Patients and methods

Eligibility criteria
Eligible patients were aged between 20 and 75 years and histologically diagnosed with epithelial ovarian, fallopian tube or primary peritoneal carcinoma, with relapse-free intervals of at least 6 months following completion of first-line platinum-based chemotherapy. Additionally, patients had measurable disease, had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, and signed informed consent. Laboratory criteria included white blood cell (WBC) count 3000-12 000/mm 3 , neutrophil count ≥1500/mm 3 , platelet count ≥75 000/mm 3 , hemoglobin level ≥10.0 g/dl, serum aspartate aminotransferase/alanine aminotransferase (AST/ALT) and alkaline phosphatase levels ≤2.5 times the upper limit of normal, serum bilirubin level less than the upper limit of normal, serum creatinine level (SCr; measured using the enzymatic method) ≤1.5 times the upper limit of normal, left ventricular ejection fraction (LVEF) ≥50% using echocardiogram, and normal electrocardiogram results.
Patients with a history of heart disease, cerebral or meningeal metastases with any symptoms, or other malignant tumors (with the exception of curatively treated basal cell or squamous cell carcinomas of the skin, or carcinoma in situ of the cervix) were excluded. Patients were also excluded if they had a prior history of anthracycline exposure.
This study was approved by the Institutional Review Boards of each participating institution, and was conducted according to principles set forth by the Declaration of Helsinki.
Study design
The present study was a multicenter, Phase II, single-arm and openlabel study. All included patients were informed of the purpose and nature of the study and provided their written consent to participate in the study prior to undergoing any study-related procedures. The primary endpoint was objective tumor response rate (RR). Secondary endpoints were toxicity and progression-free survival (PFS) and overall survival (OS) rates.
Treatment consisted of infusions of PLD (30 mg/m 2 ) at 1 mg/min, followed by CBDCA (AUC 5 mg min/ml) over 30 min. This treatment was repeated every 28 days, for a maximum of 16 cycles to avoid the myocardial damage, an adverse effect of doxorubicin. The initial dose of CBDCA was calculated using the Calvert formula (2), with an estimated glomerular filtration rate (GFR) calculated via the Jelliffe formula (3), which utilizes creatinine clearance (CCr) instead of GFR. Serum creatinine (SCr) levels, measured using the enzymatic method, were used to determine the CCr. 
Safety and efficacy evaluations
Objective RR to treatment [the proportion of patients achieving a complete response (CR) or partial response (PR)], the primary endpoint, was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) (4) . RECIST defines a CR as the disappearance of all target lesions, and a PR as a ≥30% decrease in the sum of the longest diameter (LD) of target lesions, using the baseline sum LD as the reference. Both CR and PR were verified at least once via second confirmatory measurements at least 4 weeks apart. Progressive disease (PD) is defined as either a ≥20% increase in the sum of the LD of target lesions, in comparison to the smallest sum LD recorded since the start of treatment; or as the appearance of one or more new lesions. Stable disease is defined as lesions demonstrating changes, but exhibiting insufficient shrinkage in size to constitute a PR, or insufficient increase in size to constitute PD. In patients with CA125 levels ≥50 IU/ml, response and progression were evaluated according to Gynecological Cancer Intergroup (GCIG) criteria (5, 6) . A response, based on CA125 levels, is defined as a ≥50% reduction in CA125 levels compared with a pretreatment sample. This response must be confirmed and maintained for ≥28 days. Patients can only be evaluated according to CA125 levels if they have had a pretreatment sample, taken within 2 weeks prior to starting treatment, with a value at least twice the upper limit of normal. Patients were excluded if they had pretreatment CA125 levels less than twice the upper limit of normal. Patients defined as having 'no response' were defined as those with any condition not meeting the above criteria.
Physical examinations were performed both during initial screenings and at the end of treatment; blood pressure was measured at screening, baseline, before administration of each study agent, and at the end of treatment. CA125 levels were assessed at screening, on the first day of each treatment cycle, and at the end of study. Measurements of LVEF were performed at baseline and at the end of the treatment. Any cardiac dysfunction (defined as either a decrease in LVEF to below the lower limit of normal, an absolute decrease of ≥5% from baseline, or any absolute decrease of ≥15%), symptomatic arrhythmia or congestive heart failure resulted in withdrawal from the study. Other reasons for discontinuation of therapy included CR (indicating no possibility of benefit from further treatment), disease progression, delay in treatment ≥14 days, or any adverse event (AE) that indicated withdrawal from the study.
The safety population consisted of patients who received at least one dose of the study drug. Any AEs reported by patients from the first study-related procedure until 30 days after the last dose of study agent were recorded. Special attention was given to serious or severe AEs, particularly those that resulted in death or discontinuation from the study. All clinically relevant changes in LVEF values, LVEF or echocardiogram abnormalities leading to alterations in drug therapy (i.e. dose change, delay or discontinuation), or initiation of concomitant therapy were also reported. Additional AEs associated with these study agents included PPE, cardiac events, stomatitis, neuropathic events, gastrointestinal perforation, non-gastrointestinal fistula formation, hemorrhage, arterial thromboembolic events, hypertensive crises, reversible posterior leukoencephalopathy syndrome, proteinuria, neutropenia with infection, nephrotic syndrome or congestive heart failure. Toxicities were graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0.
Statistical analysis
A sample size of 30 patients was established to provide a two-sided 95% confidence interval (CI) with a 5% type I error and 80% power. A ≤13% margin of error was observed around the assumed 60.3% overall RR in two recent Phase II studies involving PLD + CBDCA (7, 8) . Assuming a 10% dropout rate, this study aimed to enroll 33 patients. An interim analysis was not programed since this study was aimed to confirm the effectiveness and toxicities of the chemotherapy, which is demonstrated in CALYPSO study.
The primary efficacy endpoint of treatment RR and the corresponding 95% CI were calculated using per protocol set (PPS). The PPS population was defined as patients that received at least one dose of PLD + CBDCA, underwent at least one post-baseline response evaluation, and had no major protocol eligibility violations. The median times and corresponding 95% CIs for the secondary endpoints of PFS and OS were estimated using the Kaplan-Meier method (Fig. 1) .
Results
From November 2009 to November 2011, 35 patients were enrolled in this study (mean age, 58.8 years; range, 36-73 years). All patients had a baseline ECOG performance status of 0, and had received a median of five prior cycles (range, 1-14 cycles) of PTX + CBDCA. The median progression-free interval at study entry was 19.0 months (range, 6.2-141.9 months), and the mean SCr level at study entry was 0.68 mg/dl. Among participating patients, 22 had SCr levels <0.7 mg/dl, and 13 had levels ≥0.7 mg/dl.
The characteristics of patients were summarized in Table 1 . A total of 174 courses of PLD + CBDCA were administered. Patients received a median of five cycles of PLD + CBDCA (range, 1-14 cycles). Although six patients (17.1%) received two or fewer cycles, five (14.3%) received more than seven cycles. Of the participating patients, 20 (57.1%) had their PLD + CBDCA doses reduced during the course of treatment due to bone marrow suppression. Treatment was aborted in 14 patients due to neutropenia in six cases, thrombocytopenia in four cases and both neutropenia and thrombocytopenia in four cases. Of the 20 patients who had their doses reduced, 14 had SCr levels ≤0.7 mg/dl. In total, 28 patients discontinued chemotherapy. Treatment was aborted in the additional 14 patients due to allergic reaction to CBDCA in two cases, disease progression in five cases and patient request in seven cases. Seven patients completed the treatment program.
Among the 33 patients who were eligible for response evaluation, one (3.0%) achieved CR and 16 (48.5%) achieved PR, with an overall objective RR of 51.5% (95% CI, 34.5-68.6%) ( Table 2 ). The RR among 14 patients whose treatment-free interval (TFI) was >24 months was 78.6% (one achieved CR and 10 achieved PR), but the rate among 19 patients whose TFI was <24 months was significantly lower (31.6%, P = 0.013). In 22 patients with evaluable CA125 levels at entry, a response was observed in 18 patients, with a RR of 81.8% (95% CI, 65.3-98.3%). The median PFS and OS for all 35 patients were 10.7 months (95% CI, 8.1-13.2 months) and 38.8 months (95% CI, 31.0-46.7 months), respectively.
Toxicity occurrences are summarized in Table 3 . The most frequent Grade 3-4 toxicities regardless of cause were neutropenia (82.9%), thrombocytopenia (51.4%), leukopenia (45.7%) and anemia (17.1%). Six patients were administered granulocyte colony-stimulating factor, with four of these administrations occurring during the first course of chemotherapy. Platelet transfusions were not performed in this study. No significant febrile neutropenia, cardiotoxicity, neurotoxicity, Figure 1 . Kaplan-Meier plot of progression free survival and overall survival. alopecia or Grade 3 PPE was observed. No patient discontinued the treatment due to a non-hematological toxicity.
Discussion
The CALYPSO study (1) , which revealed that the PFS rates of patients with platinum-sensitive recurrent ovarian cancer were comparable among those who received PLD + CBDCA and those who received PTX + CBDCA combination chemotherapy, had a great impact on gynecologic oncologists throughout the world. Findings of this study revealed that not only was the rate of PFS improved, but the incidences of severe toxicities, including CBDCA hypersensitivity reactions, peripheral neuropathy and alopecia, were also reduced. These results suggested that PLD + CBDCA combination chemotherapy would be safe and highly effective for treatment of platinum-sensitive recurrent ovarian cancer. This study was performed to specifically assess the safety and efficacy of PLD + CBDCA combination chemotherapy in Japanese patients with platinum-sensitive recurrent ovarian cancer. The result of the primary endpoint of this study was 51.5% (95% CI, 34.5-68.6%) of RR, which revealed the significant efficacy of the treatment. The RR found in this study was almost equal to those found in previous studies (7) (8) (9) (10) (11) (12) (13) , although four patients (12.1%) were included in the analysis despite being deemed not evaluable (NE) because the radiological evaluation protocol was not followed. These results suggest that PLD + CBDCA combination chemotherapy would be an acceptable treatment option for patients with platinum-sensitive recurrent ovarian cancer.
As described previously, severe non-hematological toxicities were not observed in this study. Although Grade ≥3 neutropenia and thrombocytopenia were observed in 29 (82.9%) and 18 (51.4%) patients, respectively, granulocyte colony-stimulating factor was only administrated to six patients, and platelet transfusion was not performed in this study. These results suggest that PLD + CBDCA combination chemotherapy could be administered very safely and easily to Japanese patients with platinum-sensitive recurrent ovarian cancer, with adequate monitoring and management of bone marrow toxicities.
Two reasons were indicated for the higher incidences of Grade ≥3 neutropenia and thrombocytepenia in the present study, compared with previous studies. Hematological examinations, which were conducted at least twice during each cycle of chemotherapy in this study, were performed only once during each cycle in most of the previous studies. This difference in incidences may have been due to the difference in number of examinations, though other reasons could also be considered.
In oncologic practices, Calvert's formula (2) has been widely used to determine the dosage of CBDCA, and CCr has been substituted for GFR in the formula. The SCr level is often used to estimate CCr, with either the Jaffe method or enzymatic method used to measure the SCr level. Since Calvert's formula was based on the SCr level determined using the Jaffe method, the SCr levels determined using the enzymatic method in this study may have caused an overdose of CBDCA. Although this overdose would occur more frequently in patients with low SCr levels, as described previously (14) , this study was continued to confirm the hematological toxicity of the dose.
In this study, PLD + CBDCA doses were reduced in 20 (57.1%) of 35 patients. The reduction was noted in 14 (63.6%) of 22 patients with a SCr level <0.7 mg/dl at entry, and in 6 (46.2%) of 13 patients with a SCr level ≥0.7 mg/dl at entry. Although this difference was not statistically significant, the high incidence of thrombocytopenia may have been caused by an overdose of CBDCA due to an incorrect method of measuring SCr levels.
In conclusion, the safety and efficacy of PLD + CBDCA combination chemotherapy in patients with platinum-sensitive recurrent ovarian cancer were confirmed. Although severe hematological toxicity was a concern, this complication could be easily and safely managed by conducting hematological examinations at least twice during each cycle of chemotherapy. Toxicity could also be forestalled by utilizing different methods for measuring SCr values.
